The Medical Letter on Drugs and Therapeutics
Naldemedine (Symproic) for Opioid-Induced Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the opioid receptor antagonist naldemedine (Symproic – Shionogi) for treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain. Naldemedine is the third oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved for this indication; naloxegol (Movantik) and methylnaltrexone (Relistor) were approved earlier.

STANDARD TREATMENT – Laxatives and stool softeners are commonly used, often in combination, for initial treatment of OIC, but their efficacy is limited. Lubiprostone (Amitiza), an oral chloride channel activator, has been shown to increase the frequency of bowel movements in patients with chronic noncancer pain and OIC.1 Oral methylnaltrexone and naloxegol appear to be more effective than lubiprostone, and subcutaneous methylnaltrexone appears to be more effective than any ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Naldemedine (Symproic) for Opioid-Induced Constipation
Article code: 1535b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian